AB0780 Secukinumab sustains individual clinical responses over time in patients with psoriatic arthritis: 2-year results from a phase 3 trial, future 2
AB0780 Secukinumab sustains individual clinical responses over time in patients with psoriatic arthritis: 2-year results from a phase 3 trial, future 2